Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Aptevo Therapeutics Inc. entered into warrant inducement agreements and a private placement that together generated approximately $4.5 million in gross proceeds. Holders agreed to exercise in full 254,922 existing common stock warrants at a reduced exercise price of $4.03 per share.
In return, Aptevo issued new unregistered Inducement Warrants to purchase up to 1,274,610 shares at $4.03 per share, exercisable after required stockholder approval for five years. Under a Securities Purchase Agreement, the company also agreed to sell up to 861,708 common shares (or Pre-Funded Warrants in lieu of shares) at $4.03 per share plus Common Warrants to purchase up to 4,308,540 shares at the same exercise price.
Aptevo entered into a Registration Rights Agreement to register the resale of the shares and warrant shares, targeting filing by August 22, 2026 and effectiveness by September 26, 2026, subject to possible SEC full review. Roth Capital Partners acted as exclusive placement agent, earning a 7% fee on gross proceeds, and Aptevo plans to use net proceeds for working capital and general corporate purposes.
Aptevo Therapeutics Inc. director Zsolt Harsanyi reported a derivative exercise involving restricted stock units. On August 6, 2026, 400 RSUs were converted on a one-for-one basis into 400 shares of common stock, with no per-share exercise price reported. The RSU position was reduced to 0, and direct ownership of common stock increased to 400 shares. The RSUs originated from a grant made on August 6, 2025, which vested on the first anniversary of the grant date.
Aptevo Therapeutics Inc. reported that President and CEO Jeffrey G. Lamothe exercised 961 Restricted Stock Units on August 6, 2026. The RSUs converted on a one-for-one basis into 961 shares of common stock, which he now holds directly. The derivative RSU position was reduced to zero in this filing.
Aptevo Therapeutics Inc. reported that SVP & CFO Daphne Taylor exercised 638 Restricted Stock Units on August 6, 2026. The RSUs converted into 638 shares of common stock on a one-for-one basis. These RSUs originated from an August 6, 2025 grant of 11,500 RSUs (638 post-split) that vested on the first anniversary of the grant date.
Aptevo Therapeutics Inc. reported that officer SoYoung Kwon (SVP, GC, BD & Corp Affairs) exercised 638 Restricted Stock Units into 638 shares of common stock on August 6, 2026. The RSUs converted to common stock on a one-for-one basis, leaving 0 RSUs from this grant and resulting in 638 common shares held directly.
Aptevo Therapeutics Inc. officer Dirk Huebner (SVP, CMO) reported the vesting and settlement of 638 Restricted Stock Units (RSUs) into 638 shares of common stock on August 6, 2026. The RSUs, originally granted on August 6, 2025, converted to common stock on a one-for-one basis. In a related transaction, 156 shares of common stock were withheld by the issuer at $4.07 per share to satisfy tax withholding obligations on the RSU vesting.
Aptevo Therapeutics Inc. director Grant Grady III exercised 400 Restricted Stock Units (RSUs) into 400 shares of common stock on August 6, 2026. The RSUs convert into common stock on a one-for-one basis. Following the transaction, Grady directly holds 1,150 shares of Aptevo common stock, while the corresponding RSU position was reduced to zero.
Aptevo Therapeutics Inc. reported that Executive Chair Marvin L. White exercised and settled restricted stock units into common stock in July and August 2026. On August 6, 2026, 1,666 RSUs granted on August 6, 2025 converted into common shares, with 406 shares withheld at $4.07 per share to satisfy tax withholding obligations. On July 17, 2026, 1 RSU from a July 17, 2024 grant vested and converted into one common share.
Aptevo Therapeutics Inc. director Daniel Abdun-Nabi reported an exercise of equity awards. On August 6, 2026, 400 Restricted Stock Units converted into 400 shares of Common Stock on a one-for-one basis. The RSU position was reduced by 400 units to zero, and direct ownership of common stock increased to 400 shares following the transaction.
Aptevo Therapeutics Inc. director Barbara Lopez Kunz reported the vesting and conversion of 400 Restricted Stock Units (RSUs) into 400 shares of common stock on August 6, 2026. The RSUs convert into common stock on a one-for-one basis. These 400 RSUs were part of a grant of 7,200 RSUs (400 post-split) awarded on August 6, 2025, which vested on the first anniversary of the grant date.